Transgene

Transgene Total Assets

The Total Assets of Transgene (TNG.PA) as of Nov 18, 2026 is 42.17 M EUR. In the previous year, Total Assets was 45.22 M EUR — a change of -6.73% (lower).

Total Assets

42.17 MEUR

YoY

-6.73%

Last updated:

Total Assets of Transgene is 2024 42.17 M EUR. Total Assets of Transgene was 2023 45.22 M EUR. It decreases by -6.73% lower compared to the previous year.

The Transgene Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2017
100.87 M EUR
Jan 1, 2018
108.65 M EUR
Jan 1, 2019
115.48 M EUR
Jan 1, 2020
85.45 M EUR
Jan 1, 2021
101.84 M EUR
Jan 1, 2022
66.44 M EUR
Jan 1, 2023
45.22 M EUR
Jan 1, 2024
42.17 M EUR
The Transgene Total Assets history
YEARTotal AssetsYoY
42.17 MEUR-6.73%
45.22 MEUR-31.94%
66.44 MEUR-34.76%
101.84 MEUR+19.17%
85.45 MEUR-26.00%
115.48 MEUR+6.29%
108.65 MEUR+7.71%
100.87 MEUR-17.96%
122.95 MEUR+21.89%
100.87 MEUR-28.44%
140.95 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Transgene Stock analysis

What does Transgene do? Transgene SA is a French biotechnology company specializing in the development and production of therapeutics, with a focus on cancer medications. It has a strong patent portfolio in the field of viral vectors, which are used for targeted gene therapy. The company's main areas of operation are clinical trials, research, and production. Transgene has research and production facilities in Strasbourg and Lyon, with over 100 employees. It has established partnerships with pharmaceutical companies, including Takeda Pharmaceuticals, for the development and marketing of therapeutics. Its flagship product, OncoVir-1®, is an immunomodulator that stimulates the immune system to fight tumor cells. Another promising product is TG4010, a therapeutic vaccine for non-small cell lung carcinoma. Transgene is an emerging company with a promising portfolio of cancer therapeutics, leveraging its expertise in viral vectors and collaborating closely with industry partners to expedite the development of marketable products. Transgene is expected to play a significant role in the development of new and innovative cancer treatments. Transgene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Transgene stock

Total Assets of Transgene is 42.17 M EUR in 2024.

Total Assets of Transgene changed from 45.22 M EUR to 42.17 M EUR, representing a -6.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Transgene since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Transgene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Transgene

All Key Metrics — Transgene